RPR Screen

Syphilis is back. After decades of decline, cases have climbed sharply in many countries, including a rise in congenital syphilis passed from mother to baby. The infection is sneaky: it can hide for months or years between symptoms, quietly damaging the heart, brain, eyes, and nervous system if left untreated.

This is where the RPR (Rapid Plasma Reagin) screen comes in. It is one of the oldest and most widely used blood tests for syphilis, valued because it can tell you not just whether you've been exposed, but whether the infection appears to be active right now and whether treatment is working.

What the Test Actually Measures

RPR is a nontreponemal test, meaning it does not detect the syphilis bacterium directly. Instead, it picks up antibodies your body makes against a mix of fatty molecules (cardiolipin, lecithin, and cholesterol) that are released when tissues are damaged by infection. Because those fatty molecules also exist in healthy human cells, the test can sometimes flag other conditions that cause tissue stress, not just syphilis.

Results are reported as either non-reactive (no antibodies detected) or reactive, with a titer such as 1:1, 1:8, or 1:32. The titer is essentially a dilution number: the higher it is, the more antibody is present, and the more likely the infection is active rather than old or resolved.

Why Titers Matter More Than a Yes or No

A reactive RPR is only the start of the story. The size of the titer tells you something important about what's happening biologically. Higher numbers often signal recent or active infection, while very low numbers can reflect old, treated, or false-positive results.

In studies of adults with syphilis (particularly those with HIV coinfection and low CD4 counts), a serum RPR above 1:32 has been linked to a higher risk of neurosyphilis (infection that has reached the nervous system). Current CDC guidelines recommend spinal fluid evaluation primarily when neurologic, visual, or hearing symptoms are present, with a high titer treated as an additional risk factor (especially in people with HIV) rather than a standalone trigger. A separate analysis of cerebrospinal fluid abnormalities in 326 adults with syphilis also found that higher serum RPR titers predicted neurologic involvement.

On the other end, a meta-analysis of 17 cohort studies found that people with lower titers (around 1:32 or below) were more likely to enter a serofast state after treatment, where antibodies stay positive even though the infection is cleared. Knowing your starting titer is what makes follow-up meaningful.

Pregnancy and Congenital Syphilis

Syphilis during pregnancy is one of the most consequential infections to catch early. In a Nairobi study of 22,466 pregnant women, those with reactive RPR who went untreated had roughly four times the risk of low birth weight or stillbirth compared with uninfected mothers; antenatal treatment cut that risk substantially but did not eliminate it. In Mbarara, Uganda, about 3.8% of newborns born to mothers with reactive treponemal and RPR tests had congenital syphilis.

For infants born to mothers with infectious syphilis during pregnancy, roughly three-quarters had a non-reactive RPR by about 3 months of age after appropriate treatment, and 96% eventually had complete antibody clearance, showing that RPR is also useful for tracking newborn recovery.

Neurosyphilis and Ocular Syphilis

Syphilis can invade the brain, spinal cord, and eyes, sometimes years after the original infection. Serum RPR helps decide who needs further evaluation. While neurologic, visual, or hearing symptoms are the main reason to pursue a spinal tap, a very high RPR (1:32 or above) is one factor that can raise suspicion for neurosyphilis, particularly in people with HIV. A study of 110 patients with treated neurosyphilis found that normalization of serum RPR titer accurately predicted clearing of spinal fluid abnormalities, which can spare some people a repeat spinal tap.

A complication: a retrospective cohort of 115 patients with ocular syphilis showed that about 22% of those with vision-threatening eye involvement had a non-reactive RPR despite positive treponemal tests. RPR is a powerful tool, but it is not foolproof, especially in later disease.

Tracking Your Trend Over Time

One RPR result is a snapshot. Its real power shows up when you have more than one. A four-fold change in titer (for example, 1:32 falling to 1:8, or 1:4 rising to 1:16) is the standard signal for either successful treatment or new activity, including reinfection.

After standard treatment with benzathine penicillin G for early syphilis, roughly 70% to 90% of people show a four-fold or greater drop in RPR titer within 6 to 12 months, with figures varying by drug, dosing, and population. A retreatment study of 70 serofast patients found that an additional course produced a four-fold fall in 48.6% by 12 months. Tracking your number is what tells you whether you're on that curve.

There's an important caveat: a study of 766 people found that RPR titers can shift by four-fold within just days, even before treatment begins. That's why labs and guidelines recommend repeating RPR on the day treatment is given, so you have a true baseline to compare against later results.

When Results Can Be Misleading

RPR is famously prone to both false positives and false negatives, and knowing the common traps can save you from acting on a misleading number.

• Biological false positives: Pregnancy, autoimmune disease (especially lupus), viral infections like Epstein-Barr mononucleosis, malaria, leprosy, older age, and even some vaccines can produce a reactive RPR without syphilis. In a study of 500 pregnant women in North India, about 4% had a false-positive RPR, almost all at low titers (1:4 or below).
• Prozone phenomenon: When antibody levels are extremely high, the test can paradoxically read negative unless the lab dilutes the sample. In a large cohort study this occurred in about 0.8% of positive cases, and it is more common in pregnancy and neurosyphilis. If clinical suspicion is high, the lab should dilute and retest.
• Lab-to-lab variability: A study comparing RPR results between laboratories in Uganda found titer differences of up to three-fold for the same sample. That kind of variation can change whether a result is read as cured, stable, or worsening, so try to use the same lab over time.
• COVID-19 mRNA vaccines: A small cohort study of 38 people found that some individuals developed transient false-reactive RPR after vaccination, with effects sometimes persisting beyond 5 months.

How RPR Differs From Treponemal Tests

There are two families of syphilis blood tests. RPR is nontreponemal, meaning it tracks the body's general reaction to infection. Treponemal tests (such as TP-PA, EIA, or CIA) look for antibodies specifically against the syphilis bacterium itself. The two are complementary, not interchangeable.

What this means for you: if your RPR is reactive, the next step is a treponemal test to confirm. If only the treponemal test is positive and RPR is non-reactive, that often reflects either a past treated infection, very early infection, or a false-positive screening result that needs further workup.

Decision Pathway for an Unexpected Result

A reactive RPR is not a diagnosis by itself. What you do next depends on the pattern of findings, not just the single number.

• Reactive RPR, no confirmatory test yet: The lab should reflex to a treponemal test automatically. If it does not, request one. Do not start treatment based on RPR alone in low-prevalence settings, where false positives are common.
• Reactive RPR plus positive treponemal test: This pattern supports active or past syphilis. A clinician (ideally one experienced in STI care or infectious disease) will stage the infection based on titer, symptoms, and exposure history and decide on treatment.
• Reactive RPR with very high titer (1:32 or above) and neurologic, visual, or hearing symptoms: This combination raises concern for neurosyphilis, and a spinal tap may be warranted to check cerebrospinal fluid. Symptoms are the main trigger for lumbar puncture; a high titer adds weight, especially in people with HIV.
• Reactive RPR plus pregnancy: Confirmation and treatment should happen quickly. Untreated syphilis in pregnancy carries a roughly four-fold higher risk of low birth weight or stillbirth.
• Discordant result (treponemal positive, RPR non-reactive): A second treponemal method (such as TP-PA) is typically used to sort out true past infection from a false-positive screen.

How Often to Retest

If you have no syphilis risk factors and a non-reactive RPR, periodic rescreening is reasonable based on sexual activity, new partners, and pregnancy plans. If you are at higher risk (multiple partners, men who have sex with men, people living with HIV), more frequent screening makes sense, often every 3 to 6 months.

If you have been treated for early syphilis, the standard follow-up is RPR at 6 and 12 months, watching for the expected four-fold drop. For late or latent syphilis, monitoring extends to 6, 12, 18, and 24 months. A rise of four-fold or more after successful treatment usually signals reinfection rather than treatment failure, and warrants prompt evaluation.